The Perimenopause Pivot: Scaling Care or Scaling the Funnel?

In the world of clean tech and health deployment, I tend to ignore the funding rounds and look for where the actual infrastructure is shifting. Right now, that shift is happening in the 'perimenopause industrial complex.'

For years, hormone therapy was sidelined following a 2002 study that led clinicians to under-prescribe and patients to overestimate cancer risks. As Wired first reported, that tide has turned. The shift is being driven by a rare alignment of medical professionals, liberal feminists, and the 'Make America Healthy Again' movement, all of whom view the previous prescribing drought as a failure.

From a regulatory standpoint, the catalyst was the U.S. Food and Drug Administration's recent decision to remove 'black box' warnings from hormone therapy. This move was punctuated by a press conference featuring Robert F. Kennedy Jr., the secretary of Health and Human Services, and Alicia Jackson, the director of the Advanced Research Projects Agency for Health. Jackson, who also founded the telehealth company Evernow, framed the move as an opportunity to add up to a decade of healthy years to women's lives.

When the regulatory dam breaks, the startups move in. A SimilarWeb analysis conducted for Wired reveals a massive 490 percent spike in web traffic between 2023 and 2026 for four primary players: Midi, Winona, Alloy, and Evernow. SimilarWeb characterizes this as an 'organic demand surge.'

But is this a genuine scaling of clinical outcomes or just a highly optimized marketing funnel? The answer often lies in the gap between traditional primary care and telehealth. Wired highlights the case of Lisa Schrenk, a federal IT specialist who sought hormone therapy for treatment-resistant mood issues. Schrenk reports being repeatedly dismissed by her primary care physician and two gynecologists. It wasn't until she signed up for a video consultation with Midi, a telehealth startup, that a nurse practitioner agreed to switch her from oral contraceptives to hormone therapy.

For Schrenk, the result was a radical mental health turnaround, moving from contemplating suicide to feeling 'noticeably happier.' This suggests that for some, these startups aren't just optimizing funnels—they are providing a point of entry for care that traditional medicine is failing to deliver.

However, the mechanism of this growth is telling. The boom is fueled by a post-pandemic acceptance of virtual clinics and a growing public appetite for compounded products sold via virtual platforms. As these companies scale, the question remains whether they are expanding the medical standard of care or simply capitalizing on a rebranded buzzword to capture a millennial demographic.